Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 16/20 | 0.65 |
| ▸ | BRD9 | Q9H8M2 | 15/20 | 0.65 |
| ▸ | BRD7 | Q9NPI1 | 9/20 | 0.65 |
| ▸ | BRD2 | P25440 | 4/20 | 0.65 |
| ▸ | TAF1 | P21675 | 1/20 | 0.48 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.48 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.48 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.48 |
| ▸ | BPTF | Q12830 | 1/20 | 0.48 |
| ▸ | TAF1L | Q8IZX4 | 1/20 | 0.48 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.48 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.48 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.48 |
| ▸ | ATAD2B | Q9ULI0 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21224821 | 0.89 | BRD9 (0.63) | BRD4BRD9BRD7BRD2TAF1 | |
| SCHEMBL21227704 | 0.87 | BRD9 (0.64) | BRD4BRD9BRD7BRD2TAF1 | |
| SCHEMBL21227686 | 0.80 | BRD4 (0.42) | BRD4BRD9BRD7BRD2 | |
| SCHEMBL19869713 | 0.79 | BRD9 (1.00) | BRD4BRD9BRD7BRD2TAF1 | |
| SCHEMBL21224452 | 0.78 | BRD9 (0.74) | BRD4BRD9BRD7BRD2TAF1 | |
| SCHEMBL21224692 | 0.78 | BRD9 (0.46) | BRD4BRD9BRD7BRD2TAF1 | |
| SCHEMBL19857679 | 0.76 | BRD9 (1.00) | BRD4BRD9BRD7BRD2TAF1 | |
| Formic Acid SCHEMBL22291442 | 0.74 | BRD9 (0.45) | BRD4BRD9BRD7BRD2TAF1 | |
| SCHEMBL19857630 | 0.72 | BRD9 (1.00) | BRD4BRD9BRD7BRD2TAF1 | |
| SCHEMBL21224710 | 0.71 | BRD9 (0.67) | BRD4BRD9BRD7BRD2TAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773085-B2 | Methods and compounds for treating disorders | FOGHORN THERAPEUTICS INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773085-B2 | Methods and compounds for treating disorders | FOGHORN THERAPEUTICS INC. (US) | 2023-10-03 | — | — | US | disclosed |
| CN-112236172-A | Methods and compounds for treating disorders | 福宏治疗公司 | 2021-01-15 | — | — | CN | disclosed |
| US-20210009568-A1 | METHODS AND COMPOUNDS FOR TREATING DISORDERS | FOGHORN THERAPEUTICS INC. | 2021-01-14 | — | — | US | disclosed |
| EP-3746135-A1 | METHODS AND COMPOUNDS FOR TREATING DISORDERS | Foghorn Therapeutics Inc. (US) | 2020-12-09 | — | — | EP | disclosed |
| WO-2019152440-A1 | METHODS AND COMPOUNDS FOR TREATING DISORDERS | FOGHORN THERAPEUTICS INC. (US) | 2019-08-08 | — | — | WO | disclosed |
| WO-2019152440-A1 | METHODS AND COMPOUNDS FOR TREATING DISORDERS | FOGHORN THERAPEUTICS INC. (US) | 2019-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773085-B2 | Methods and compounds for treating disorders | VHL, TFEB, BECN1 | BRD4 57/4885BRD9 330/4885BRD7 263/4885 |
| US-20210009568-A1 | METHODS AND COMPOUNDS FOR TREATING DISORDERS | VHL, TFEB, BECN1 | BRD4 57/4885BRD9 330/4885BRD7 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.